January 18, 2022 - January 21, 2022

Alkosign IPO Review & Recommendations

Dilip Davda recommend to "Avoid" the IPO.

Alkosign IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated
Count	0	0	0	1	0
%	0.00	0.00	0.00	100.00	0.00

Alkosign IPO Analysis By Brokers/Analysts

Reviewer	Recommendation	Past Reviews
Dilip Davda	Avoid

Alkosign IPO Review by Dilip Davda (Avoid)

[Dilip Davda] The company has shown just 20 months working with the last eight months reporting negative earnings. The company has a long gestation period to migrate to the main board as its post IPO equity remains small. The issue expenses indicate a fully structured IPO with pre-funding arrangements. It operates in a highly competitive and fragmented segment. Based on its financial data, the issue is exorbitantly priced. There is no harm in avoiding this issue. Read detail review...

Alkosign IPO Review by Members

Alkosign IPO Reviews, analysis and views by popular members. Read Alkosign Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Alkosign IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid

Member	Review
No recommendation found. Be the first to post the recommendation.

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.